Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | DPP4 | P27487 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.70 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.70 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.70 |
| ▸ | GAPDH | P04406 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | STAT6 | P42226 | 1/20 | 0.70 |
| ▸ | PI4KA | P42356 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.70 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.70 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.70 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.70 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873362 | 0.90 | ADORA3 (0.72) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL3447141 | 0.90 | ADORA1 (0.71) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL3698839 | 0.90 | ADORA3 (0.72) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL8164443 | 0.89 | P2RY1 (0.68) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 | |
| Water SCHEMBL4262656 | 0.88 | ADORA1 (0.71) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL15338536 | 0.88 | ADORA1 (0.74) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL15926827 | 0.88 | ADORA1 (0.74) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL15338502 | 0.88 | ADORA1 (0.74) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL15788449 | 0.88 | ADORA1 (0.74) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL384075 | 0.88 | ADORA1 (0.74) | ADORA1ADORA3ADORA2AADORA2BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759321-B2 | Compounds for the treatment of pain | CAMBRIDGE BIOTECHNOLOGY LTD (GB) | 2010-07-20 | — | — | US | disclosed |
| US-20080221060-A1 | Adenosine derivatives for treatment of pain and/or inflammation; diabetes | BIOVITRUM AB (PUBL) (SE) | 2008-09-11 | — | — | US | disclosed |
| EP-1603577-B1 | COMPOUNDS FOR THE TREATMENT OF PAIN | CAMBRIDGE BIOTECHNOLOGY LTD (GB) | 2008-07-16 | — | — | EP | disclosed |
| US-20070066559-A1 | Compounds for the treatment of pain | BIOVITRUM AB (PUBL) (SE) | 2007-03-22 | — | — | US | disclosed |
| EP-1749016-A2 | ADENOSINE RECEPTOR AGONISTS | Cambridge Biotechnology Ltd (GB) | 2007-02-07 | — | — | EP | disclosed |
| EP-1603577-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | Cambridge Biotechnology Ltd (GB) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005084653-A2 | ADENOSINE RECEPTOR AGONISTS | CAMBRIDGE BIOTECHNOLOGY LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| WO-2004078183-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | CAMBRIDGE BIOTECHNOLOGY LTD (GB) | 2004-09-16 | — | — | WO | disclosed |
| WO-1998016539-A1 | NOVEL THERAPEUTICALLY ACTIVE ADENOSINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221060-A1 | Adenosine derivatives for treatment of pain and/or inflammation; diabetes | ADORA3, ADORA2B, P2RX3 | ADORA1 21/4885ADORA3 1/4885ADORA2A 9/4885 |
| US-20070066559-A1 | Compounds for the treatment of pain | OPRK1, OPRL1, OPRM1 | ADORA1 361/4885ADORA3 167/4885ADORA2A 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.